Aegis Capital Lifts PT on Oramed Pharma (ORMP) to $30 Ahead of ORMD-0801 Phase 2a Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
MLV & Co. Starts Oramed Pharma (ORMP) at Buy
January 7, 2014 4:55 PM ESTMLV & Co. initiated coverage on Oramed Pharma (NASDAQ: ORMP) with a Buy. PT $27.00.
For an analyst ratings summary and ratings history on Oramed Pharma click here. For more ratings news on Oramed Pharma click here.
Shares of Oramed Pharma closed at $18.15 yesterday, with a 52 week range of $0.31-$19.29.... More
